GMP Peptide Retatrutide 2381089-83-2 10mg 12mg 25mg Purity >99.5%, 120% Overfilled

• CAS No.: 2381089-83-2
• Formula: C221h342n46o68.Xc2hf3o2
• EINECS: N/a
• Type: Sterile Lyophilized Powder
• Appearance: Powder
• Quality: Pharmaceutical Grade
• Model NO.: LY-3437943
• Colour: White
• Purity: > 99.5% by HPLC
• Molecular Weight: 4731.33 (Free Base)
• Synonyms: Ly3437943
• Application: Nad+ Slows The Aging Process, Restores Neurologic
• Shipping: Room Temperature in Continental Us
• Storage: Sealed Storage, Away From Moisture
• Clinical Trial: Type 2 Diabetes|Obesity|Overweight
• Transport Package: Vials
• Specification: 5mg, 10mg, 12mg, 15mg, 20mg, 1g
• Trademark: ZPHC
• Origin: China
• Production Capacity: 100, 000 Vials Per Month

Product Description

 

Product Description

Retatrutide is a 39 amino acid single peptide with triple agonist activity at the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). The backbone is conjugated to a C20 fatty diacid moiety at position 17.
Retatrutide has a Glucose-dependent insulinotropic polypeptide (GIP) peptide backbone, which then contains three non-coded amino acids. Aib2 (α-amino isobutyric acid) residues at positions 2 and 20 provide stability against Dipeptidyl Peptidase 4 (DPP4) cleavage and contribute to GIP activity. αMeL13 (α-methyl-L-leucine)at position 20 also contributes to GIP and glucagon activity.

Retatrutide can be used for the research of obesity obesity, diabetes, and fatty liver disease. It is a works in three ways: stimulating insulin release, suppressing appetite, and promoting fat breakdown.

Description

Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). 

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT05929079	Eli Lilly and Company	Type 2 Diabetes|Obesity|Overweight|Obstructive Sleep Apnea	July 11, 2023	Phase 3
NCT04867785	Eli Lilly and Company	Type 2 Diabetes	May 13, 2021	Phase 2
NCT05882045	Eli Lilly and Company	Obesity|Cardiovascular Diseases	May 30, 2023	Phase 3
NCT05929066	Eli Lilly and Company	Obesity|Overweight|Knee Pain Chronic|Knee Osteoarthritis|Obstructive Sleep Apnea	August 7, 2023	Phase 3
NCT05916560	Eli Lilly and Company	Healthy|Hepatic Insufficiency	July 13, 2023	Phase 1
NCT05931367	Eli Lilly and Company	Obesity|Overweight|Osteo Arthritis Knee	August 28, 2023	Phase 3
NCT05611957	Eli Lilly and Company	Healthy|Renal Insufficiency	November 16, 2022	Phase 1
NCT05959096	Eli Lilly and Company	Healthy	July 18, 2023	Phase 1
NCT06003465	Eli Lilly and Company	Healthy	August 29, 2023	Phase 1
NCT04881760	Eli Lilly and Company	Obesity|Overweight	May 20, 2021	Phase 2
NCT03841630	Eli Lilly and Company	Healthy	March 13, 2019	Phase 1
NCT04823208	Eli Lilly and Company	Diabetes Mellitus, Type 2	May 24, 2021	Phase 1
NCT05936151	Eli Lilly and Company	Overweight or Obesity|CKD|Type 2 Diabetes	July 20, 2023	Phase 2
NCT05548231	Eli Lilly and Company	Overweight|Obesity	October 24, 2022	Phase 1
NCT04143802	Eli Lilly and Company	Diabetes Mellitus, Type 2	December 18, 2019	Phase 1
NCT05445232	Eli Lilly and Company	Obesity	July 8, 2022	Phase 1

 

Molecular Weight

4731.33 (free base)

Formula

C₂₂₁H₃₄₂N₄₆O₆₈._xC₂HF₃O₂

Appearance

Solid

Color

White to off-white

Sequence

Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

SMILES

[LY3437943 (TFA salt)]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

 

Test reports

Retatrutide 3rd lab test reports

Services